Compare VENUS REMEDIES with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ELDER PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES ELDER PHARMA VENUS REMEDIES/
ELDER PHARMA
 
P/E (TTM) x -1.0 -0.2 - View Chart
P/BV x 0.1 0.1 72.0% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   ELDER PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
ELDER PHARMA
Jun-14
VENUS REMEDIES/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs126380 33.1%   
Low Rs61188 32.5%   
Sales per share (Unadj.) Rs301.8491.2 61.4%  
Earnings per share (Unadj.) Rs-24.9-3.2 781.7%  
Cash flow per share (Unadj.) Rs2.514.4 17.7%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs293.3376.5 77.9%  
Shares outstanding (eoy) m12.3420.54 60.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.30.6 53.6%   
Avg P/E ratio x-3.8-89.3 4.2%  
P/CF ratio (eoy) x36.719.7 186.4%  
Price / Book Value ratio x0.30.8 42.3%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,1545,833 19.8%   
No. of employees `0000.9NA-   
Total wages/salary Rs m3932,179 18.0%   
Avg. sales/employee Rs Th4,026.1NM-  
Avg. wages/employee Rs Th425.0NM-  
Avg. net profit/employee Rs Th-331.8NM-  
INCOME DATA
Net Sales Rs m3,72410,089 36.9%  
Other income Rs m23257 8.8%   
Total revenues Rs m3,74710,346 36.2%   
Gross profit Rs m395-792 -49.9%  
Depreciation Rs m338361 93.6%   
Interest Rs m3542,756 12.9%   
Profit before tax Rs m-275-3,653 7.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m32125 25.2%   
Profit after tax Rs m-307-65 469.6%  
Gross profit margin %10.6-7.8 -135.1%  
Effective tax rate %-11.5-3.4 335.0%   
Net profit margin %-8.2-0.6 1,272.3%  
BALANCE SHEET DATA
Current assets Rs m2,6389,240 28.5%   
Current liabilities Rs m2,3059,998 23.1%   
Net working cap to sales %8.9-7.5 -119.1%  
Current ratio x1.10.9 123.8%  
Inventory Days Days13546 292.5%  
Debtors Days Days4660 77.3%  
Net fixed assets Rs m4,87110,124 48.1%   
Share capital Rs m123206 60.0%   
"Free" reserves Rs m3,4965,582 62.6%   
Net worth Rs m3,6197,734 46.8%   
Long term debt Rs m1,3744,889 28.1%   
Total assets Rs m7,50922,882 32.8%  
Interest coverage x0.2-0.3 -68.5%   
Debt to equity ratio x0.40.6 60.1%  
Sales to assets ratio x0.50.4 112.5%   
Return on assets %0.611.8 5.4%  
Return on equity %-8.5-0.8 1,003.5%  
Return on capital %1.622.3 7.1%  
Exports to sales %03.0 0.0%   
Imports to sales %13.90.4 3,246.8%   
Exports (fob) Rs mNA307 0.0%   
Imports (cif) Rs m51743 1,198.5%   
Fx inflow Rs m0307 0.0%   
Fx outflow Rs m517125 412.2%   
Net fx Rs m-517181 -284.9%   
CASH FLOW
From Operations Rs m51411,754 4.4%  
From Investments Rs m-123-561 22.0%  
From Financial Activity Rs m-387-6,762 5.7%  
Net Cashflow Rs m44,432 0.1%  

Share Holding

Indian Promoters % 32.9 39.6 83.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 7.5 2.4%  
FIIs % 0.6 16.8 3.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 36.1 183.9%  
Shareholders   20,121 16,479 122.1%  
Pledged promoter(s) holding % 36.4 77.6 46.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   ALKEM LABORATORIES  PLETHICO PHARMA  GLENMARK PHARMA  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 20, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS